GL1X · GenesisL1 explorer

MolNFT v1 · #132470 · protein

Pandda analysis group deposition -- AAR2/RNASEH in complex with fragment F2X-entry C05, dmso-free

5R0B · Pre-mRNA-splicing factor 8: “Pandda analysis group deposition -- AAR2/RNASEH in complex with fragment F2X-entry C05, dmso-free”. X-ray diffraction, 1 ligand (SY7), 6 pockets (best druggability 0.43). MolNFT v1 #132470 on GenesisL1…

PDB
5R0B
Type
protein
Length
537 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Pre-mRNA-splicing factor 8; A1 cistron-splicing factor AAR2
UniProt
P33334, P32357
Ligands
SY7
Pockets
6 · best druggability 0.43

Structure

x-ray diffraction · 2 distinct chains · 45% helix, 19% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APre-mRNA-splicing factor 8protein23746% helix, 20% strandP33334
BA1 cistron-splicing factor AAR2protein30045% helix, 18% strandP32357

Ligands and binding sites

  • SY7 · 2-methoxy-4-[[(4~{S},5~{S})-2,4,5-tris(2-methoxypyridin-4-yl)imidazolidin-1-yl]methyl]pyridine · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11320.430.7617empty
21140.370.7318empty
3640.360.7816empty
4870.350.7511empty
5880.340.7417empty

Interfaces

1 interface between chains.

  • A–B · 465 Ų buried · 4 hydrogen bonds · protein-protein

Compared structures

  • 5R0B · PanDDA analysis group deposition -- Aar2/RNaseH in complex with fragment F2X-Entry C05… · the same entry in another collection · chain A against A, TM-score 1.00
  • P32357 · AlphaFold monomer V2.0 prediction for A1 cistron-splicing factor AAR2 (P32357) · a predicted model of the same protein · chain B against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.